Cartesian Therapeutics (RNAC) reported a "watershed moment" for its autoimmune-disease focused CAR-T treatment on Tuesday, but the biotech stock plunged in premarket trades.
The biotech company tested its drug, Descartes-08, in patients with generalized myasthenia gravis, an autoimmune condition that causes muscle weakness and fatigue. After three months, 71% of patients who received Cartesian's drug achieved at least a five-point improvement on a 50-point scale of symptoms. In comparison, just 25% of placebo recipients hit the same bar.
"These data mark a watershed moment for the field, representing the first-placebo controlled study of a CAR-T cell therapy in autoimmune disease," Leerink Partners analyst Thomas Smith said in a report to clients.
But in premarket trades on today's stock market, the biotech stock plummeted 17.8% to 20.01.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.